Karuna Therapeutics, Inc. Karuna Therapeutics, Inc.

Karuna Therapeutics, Inc.

KRTX

Classement en actions #2112
Operating as a clinical-stage biopharmaceutical firm, Karuna Therapeutics, Inc.... Operating as a clinical-stage biopharmaceutical firm, Karuna Therapeutics, Inc. is dedicated to pioneering innovative therapies for individuals afflicted by psychiatric and neurological disorders. Its primary investigational compound, KarXT, is an oral agent designed to modulate muscarinic receptors. Currently in Phase III clinical trials, KarXT is being evaluated for several indications: the treatment of acute psychosis in schizophrenia patients, the amelioration of central nervous system conditions (including the negative and cognitive symptoms associated with schizophrenia and general psychosis), and the management of dementia-related psychosis. Beyond KarXT, the firm is also advancing a pipeline of other drug candidates that interact with muscarinic receptors. Karuna Therapeutics, Inc. has forged several strategic partnerships, encompassing licensing agreements with Eli Lilly and Company and Zai Lab (Shanghai) Co., Ltd., a patent license with PureTech Health LLC, and drug discovery collaborations with Charles River Laboratories and PsychoGenics, Inc. Established in 2009, the enterprise initially operated under the name Karuna Pharmaceuticals, Inc., before officially adopting its current corporate identity, Karuna Therapeutics, Inc., in March 2019. Its corporate headquarters are located in Boston, Massachusetts.
Prix de l'action
$329.83
Dernière synchronisation: 2024-03-18
Capitalisation boursière
$9.75B
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Karuna Therapeutics, Inc. (KRTX)

Catégorie

Healthcare
Historique du rendement du dividende pour Karuna Therapeutics, Inc. (KRTX)
Le rendement du dividende (TTM) de Karuna Therapeutics, Inc. (symbole boursier : KRTX) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Karuna Therapeutics, Inc. (KRTX) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.17%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH